



Florin-Andrei Taran

Kontakt

Florin-Andrei Taran

Publikationen (11)

Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. *Breast Cancer Res Treat* 2022

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". *Breast* 2021; 55:138-139.

Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. *BMC cancer* 2020; 20:1091.

Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. *Cancers (Basel)* 2020; 12

Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. *Breast* 2020; 54:88-95.

Kolberg H, Wallwiener M, Overkamp F, Tesch H, Ettl J, Luftner D, Müller V, Schütz F, Fasching P, Taran F, Hartkopf A, Janni W, Schneeweiss A, Fehm T, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux M, Brucker S. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. *Geburtshilfe Frauenheilkd* 2019; 79:470-482.

Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. *Cancers (Basel)* 2018; 11

Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. *Geburtshilfe Frauenheilkd* 2017; 77:1281-1290.

De Gregorio A, Janni W, Fasching P, Taran F, Hartkopf A, Jaeger B, Meier-Stiegen F, Pantel K, Schneeweiss A, Mueller V, Riethdorf S, Alunni-Fabbroni M, Trapp E, Rack B, De Gregorio N, Scholz C, Huober J, Friedl T, Fehm T. Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer. *JCO Precis Oncol* 2017; 1:1-12.

Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. *Breast* 2017; 37:42-51.

Schramm A, Janni W, Wallwiener D, Taran F, Hartkopf A, Meier-Stiegen F, Pantel K, Schneeweiss A, Müller V, Alunni-Fabbroni M, Trapp E, Rack B, Huober J, De Gregorio N, Scholz C, Schochter F, Friedl T, Fehm T. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. *Arch Gynecol Obstet* 2015; 293:271-81.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch